Advanced Medical Solutions Group (LSE:AMS) remains in an Offer Period following the proposed Takeover by US adhesives company H.B. Fuller, which was announced in late June 2026. A flurry of Takeover Code disclosures on 6 November 2026, including a Rule 2.9 announcement, shows that trading in the shares continues to be closely tracked as the deal moves through its process.

The offer

H.B. Fuller announced on 24 June 2026 that it would acquire Advanced Medical Solutions, at a reported price of 285 pence per share. The terms valued the shares at about £715 million, or roughly $942 million. The AMS board was reported to have unanimously backed the terms, and the shares rose around 16% when the news broke on 25 June.

The Rule 2.9 announcement on 6 November 2026 recorded 221,129,306 ordinary shares of 5 pence each in issue, all admitted to AIM, with none held in treasury.

What the company does

Advanced Medical Solutions, based in Cheshire, develops and manufactures medical products for wound closure, wound care and surgical applications. LSE:AMS's portfolio includes tissue adhesives and sealants, alongside advanced wound dressings. It sells both under its own brands and as a supplier to larger medical device groups, and has built a reputation as one of the larger healthcare companies quoted on AIM.

Recent commercial news

A separate announcement on 9 November 2026 said the medical technology contract services organisation NAMSA and Advanced Medical Solutions had agreed a preferred partnership. Earlier in 2025, a directorate change had also been notified to the market in March.

Financial and Dividend picture

Because the company is in an offer period, investor attention is focused on the price attached to the deal rather than on conventional Earnings forecasts. The 285 pence offer represents the headline value for shareholders, and the Takeover Code restricts what the company can say about its prospects while the bid is live. Shareholders wanting the latest dividend, Revenue and profit details should consult the company's most recent annual and interim reports.

Sector and index context

The FTSE AIM All Share Index covers a wide range of growth companies, and healthcare and medical technology businesses form one of its more established groups. An agreed bid for an AIM constituent that has grown to a Market Value of several hundred million pounds highlights a broader theme in London, where overseas strategic buyers have shown interest in UK-listed companies that trade at what they regard as attractive valuations. If the deal completes, Advanced Medical Solutions (LSE:AMS) would leave the index.

Key risks

Offer situations carry their own risks. Completion normally depends on Shareholder approval, court processes and any regulatory clearances, and conditions can Fail or be delayed. If the deal were to lapse, the share price could move back towards its pre-offer level. Reported dissent from activist shareholders at H.B. Fuller itself is a reminder that the acquirer's own investors have views on the transaction, although the target board has backed it.

What to watch next

Readers should watch for the scheme or offer documentation, the dates of shareholder meetings, the receipt of regulatory approvals and the expected completion date. Further Form 8 disclosures will continue to show who is buying and selling the shares during the offer period. Any update on the NAMSA Partnership may also indicate how LSE:AMS is positioning its product development in the meantime.